Avacta Group Plc (AVCT.L), a company focused on innovative, targeted oncology drugs, said on Tuesday that it has appointed David Liebowitz as Chief Medical Officer.
Liebowitz joins Avacta from Inovio Pharmaceuticals Inc. (INO), where he served as Senior Vice President of early-stage clinical development, overseeing the clinical strategy for DNA-based vaccines and immunotherapies.
Prior to that, he held senior roles at Xencor, Vaxart, and Amgen, with a consistent focus on oncology, immunotherapy, and translational science.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.